

Aging of the striatum: mechanisms and interventions

Hiroyuki Umegaki · George S. Roth ·
Donald K. Ingram

Received: 7 December 2007 / Accepted: 3 June 2008 / Published online: 3 July 2008
© American Aging Association 2008

Abstract Motor function declines with increasing adult age. Proper regulation of the balance between dopamine (DA) and acetylcholine (ACh) in the striatum has been shown to be fundamentally important for motor control. Although other factors can also contribute to this age-associated decline, a decrease in the concentration and binding potential of the DA D₂ receptor subtype in the striatum, especially in the cholinergic interneurons, are involved in the mechanism. Our studies have shown that gene transfer of the DA D₂ receptor subtype with adenoiviral vectors is effective in ameliorating age-associated functional decline of the striatal cholinergic interneurons. These achievements confirm that an age-associated decrease of D₂R contributes functional alteration of the interaction of DA and ACh in the striatum and demonstrate that these age-associated changes indeed are modifiable.

Keywords Dopamine receptor D₂ · Viral vector · Acetylcholine · Interneuron

Introduction

Motor function declines with increasing adult age (Potvin et al. 1980; Kolb et al. 1998). The mechanisms of this age-associated decline of motor function are complex and multifactorial. They include changes in musculoskeletal architecture (Lexell 1997; Dutta et al. 1997) and both peripheral and central nerve conduction (Dorfman and Bosley 1979; Delbono 2003).

The nigrostriatal system has also been implicated in the decline of motor function in senescence. Pharmacological interference of dopamine (DA) synthesis (Rech et al. 1966), blockade of receptor binding of DA (Carp and Anderson 1979), or destruction of dopaminergic neurons (Kozlowski and Marshall 1981) have been demonstrated to induce motor functional impairment similar to that observed in aged animals. Age-related structural alterations in the nigrostriatum system with aging have also been established. Although the issue of an age-related decrease in the number of nigral cells remains controversial (Stark and Pakkenberg 2004), age-related decline in striatal DA levels (Carlsson and Winblad 1976) and DA receptors, specifically D₂R subtype (Morgan and Finch 1988; Joseph et al. 1990), have been repeatedly reported. Moreover, almost 30 years ago, Marshall and Berrios demonstrated that

H. Umegaki (✉)
Department of Geriatrics,
Nagoya University Graduate School of Medicine,
65 Tsuruma-cho, Showa-ku, Nagoya, Aichi, Japan
e-mail: umegaki@med.nagoya-u.ac.jp

G. S. Roth
GeroScience, Inc.,
Pylesville, MD 21132, USA

D. K. Ingram
Nutritional Neuroscience and Aging Laboratory,
Pennington Biomedical Research Center,
Louisiana State University System,
6400 Perkins Road, Baton Rouge, LA 70808, USA

DA injections improved swimming performance in aged rats (Marshall and Berrios 1979), and pharmacological interventions to increase the DA receptor density have been shown to enhance motor function in senescent rats (Joseph and Roth 1988a). Taken altogether, the alteration of dopaminergic systems may contribute the age-associated motor functional decline.

Structure of the striatum

The striatum is one of the main structures of the basal ganglia, which receives various inputs from several brain regions, including the cortex, substantia nigra, and thalamus. Principal projecting neurons in the striatum are medium-sized cells (10–20 μm diameter) with spiny dendrites [medium spiny (MS) cells]. MS cells occupy 95% of the striatal neuronal population. The other neuronal population consists of interneurons, and several types of interneurons have been identified. There are three types of GABAergic interneurons in the striatum, distinguished by neurochemical characteristics, and cholinergic interneurons also have been identified (Tepper and Bolam 2004).

Cholinergic interneurons are the largest aspiny neurons (20–50 μm diameter, 300–2,000 μm^2), accounting for less than 2% of total neuronal population in the striatum (Pisani et al. 2000, 2001). The axons of interneurons extend well into the striatum and also possess widespread dendritic trees (Graybiel 1990). In terms of localization, these cells form pairs with MS cells and provide modulatory interactions on output signals from the striatum (Mensah 1980; Pickel and Chan 1991). Based on these features, these interneurons appear able to integrate synaptic inputs and project over large regions within the striatum.

Compared with other brain regions, the striatum possesses one of the highest contents of ACh despite the relatively small occupancy of the cholinergic interneurons in striatal neuronal populations. Several studies demonstrated that cholinergic interneurons receive dopaminergic inputs from the substantia nigra and glutamatergic inputs from the neocortex (Dimova et al. 1993; Chang 1988; Kubota et al. 1987; Bolam and Bennett 1995; Lapper and Bolam 1992). However, not all the reports have confirmed dopaminergic terminals at synapses of cholinergic interneurons (Pickel and Chan 1990). Because tyrosine hydroxy-

lase (TH) and choline acetyl transferase (ChAT) immunoreactive terminals are closely positioned, possibly to allow simple diffusion of neurotransmitters as they are released, the possibility that DA is regulating the activity of cholinergic cells in a non-synaptic way also exists (Stoof et al. 1992) as well as in a synaptic way. Reciprocally, ACh also transmits the inputs to DA neurons by both synaptic and non-synaptic mechanisms (Contant et al. 1996).

Functional interactions between dopaminergic and cholinergic neurons in the striatum

Proper regulation of the balance between DA and ACh in the striatum has been known to be fundamentally important for motor control (Di Chiara et al. 1994; Calabresi et al. 2000). The apomorphine-induced rotational model has been well established to evaluate asymmetrical D_2R distributions in the striata, typically following a unilateral injection of 6-hydroxydopamine (6OHDA) into the substantia nigra (Pycock 1980). The unilateral dopaminergic innervation to the striatum is markedly reduced by the toxic effects of 6OHDA, and upregulation of striatal D_2R in the lesioned side is observed. With this alteration in the nigrostriatal system, following a systemic injection of the DA agonist, apomorphine, 6OHDA-lesioned rats display a stereotypic rotational behavior in the direction contralateral to the lesioned side where the D_2R upregulation occurs. Kaneko and co-workers demonstrated that the neurochemical ablation of unilateral cholinergic neurons in the striatum could induce ipsilateral rotational behavior following systemic apomorphine (DA agonist) injection, suggesting cholinergic dysfunction could also change the dopaminergic neuronal functions (Kaneko et al. 2000). These experiments clearly demonstrated that ACh-DA interaction was regulated to coordinate striatal synaptic integration.

Regarding clinical issues, patients with Parkinson's disease, who have reduced DA binding to the striatal receptors because of dopaminergic neuronal loss in the substantia nigra, show impaired extrapyramidal motor function (Fahn 2003). Some of the symptoms of this disease can also be alleviated by inhibiting ACh activities (Berg et al. 1987). These findings also suggest that ACh-DA interactions in the striatum are important in regulating motor function.

Yan et al. (1997) reported that all the cholinergic interneurons possess the DA D₂ subtype of receptor, and 90% of the cells coexpressed D₁ type. Dopaminergic regulation of striatal ACh is reciprocal, i.e., DA D₂ receptor is inhibitory, while the D₁ receptor is stimulatory (DeBoer et al. 1996; Di Chiara et al. 1994). Activation of D₂R in cholinergic interneurons reduces the N-type calcium currents through the protein kinase C pathway to modulate the excitability of the cell and reduce ACh release (Yan et al. 1997; Pisani et al. 2000; Maurice et al. 2004; Stoof et al. 1992)

Age-associated changes of DA and ACh interactions in the striatum

An age-associated decrease in the concentration or binding potential of D₂R in the striatum has been documented in a variety of species ranging from rodents to humans. The hypothesized mechanisms of these decrements are both molecular and cellular (Roth and Joseph 1994). At the molecular level, the biosynthesis of the D₂R has been shown to be reduced in the aged striatum (Henry and Roth 1984; Henry et al. 1987; Norman et al. 1987), and the concentration of mRNA for this receptor also decreases with advancing age (Della Vedova et al. 1992; Weiss et al. 1992). At the cellular level, approximately 20% of the striatal neurons are lost (Han et al. 1989). In effect, in the mammalian brain there appears to be about a 30–50% loss of D₂R in the aged striata.

No direct evidence has indicated the age-associated decrease of D₂R on the interneuron. However, Zhang and co-workers evaluated D₂R mRNA levels in the striatum neurons according to cellular size. They concluded that the significant decrease in D₂R mRNA appeared in positive large neurons (over 210 μm^2), which were probably were interneurons (Zhang et al. 1995).

Age-associated changes in the striatal cholinergic system have also been reported. The baseline release of ACh in the striatum was decreased in aged rats compared with young rats (Wu et al. 1988; Wang et al. 2007). A decline of cholinergic activity in the striatum was suggested by several studies (Sherman and Friedman 1990; Ogawa et al. 1994; Zambrzycka et al. 2002). The activity of cholinesterase, which degrades ACh, was also decreased by age (Das et al. 2001). Using a striatal slice preparation, Joseph and Roth (1988b) reported

reduced inhibition of ACh release by apomorphine in aged rats compared with young and middle-aged rats.

We also investigated the age-associated changes of DA and ACh interactions in the striatum by in-vivo microdialysis. The effects of different concentrations of a D₂R agonist, quinpirole, on the striatal ACh release in three groups of rats at different ages (6-, 15-, 25-months old) were examined. The infusion of quinpirole into the striatum decreased ACh levels in all three age group as shown in Fig. 1. Significant differences between the effects of the two doses of quinpirole were found in the young and old rats ($P < 0.05$) (Fig. 1a,c), but not in the middle-aged rats (Fig. 1b). In the mean levels of ACh release (120–220 min) suppressed by quinpirole, there were significant differences between the middle-aged and old rats ($P < 0.05$) at the dose of 0.1 μM quinpirole (Fig. 2a), and between the young and old rats ($P < 0.05$) at the dose of 1 μM quinpirole (Fig. 2b). These data suggested that the striatal DA-ACh interaction was affected in aged animals (Kurotani et al. 2003). The reason why there were no dose-dependent effects in the middle-aged rats was unclear; however, we speculate that supersensitivity of D₂R induced by a slight decrease of D₂R numbers in middle-aged rats may exert an almost full response by a lower dose of D₂R agonist.

After considering the results discussed above, we can offer the following hypothesis: the age-related decrease in D₂R concentration could lead to a “cascade” of intrastriatal effects that initially change the reciprocal inhibitory control between ACh and DA, leading to diminutions in motor performance. We could propose that one way of testing this hypothesis would be to determine if restorations of age-associated decreased D₂R signaling in the striatal interneurons could ameliorate the functional impairments of ACh-DA interactions.

Interventions to ameliorate the decline in age-associated DA-ACh interactions in the striatum

There are several ways of supplementing dopaminergic input in aged nigrostriatal systems. One of these ways is by introducing intrastriatal nigral grafts. Such grafts have been shown to improve movement coordination in aged rats (Gage et al. 1983), which suggested that age-associated motor functional impairment was at least partly due to reduced striatal dopaminergic input, and the supplement of dopami-




Fig. 1 Effects of quinpirole on striatal ACh release. Time courses of ACh release in young (**a**, $n=6$), middle-aged (**b**, $n=7$), and old (**c**, $n=7$) rats are shown. The results are expressed as a percentage of the basal levels (calculated as the mean of the three samples before drug perfusion). Each point represents the mean \pm SD. Quinpirole at the concentration of $0.1 \mu\text{M}$ (●) or

$1 \mu\text{M}$ (○) was perfused through the microdialysis probe from 60 to 240 min after the experiment was begun. Repeated-measures ANOVA revealed a significant effect of dose in young (**a**) ($P=0.011$), and in old rats (**c**) ($P=0.043$), but no significant difference ($P=0.71$) in middle-aged rats (**b**)

nergic input could ameliorate these impairments. Another important suggestion which these graft studies gave us was that intrastriatal nigral grafts restored cholinergic interneuronal function via actions at DA receptors located on interneurons (Herman et

al. 1988; Jackisch et al. 1991). The increased input of DA receptors on interneurons is possibly needed to restore the age-associated functional decline in DA-ACh interactions and could ameliorate motor function deficits (Puschban et al. 2000).




Fig. 2 Attenuation of striatal D₂R-mediated ACh output with age. Percent decrease of ACh output from the baseline is presented as the mean \pm SD. In 0.1 μ M quinpirole (a), statistical significance was revealed between the middle-aged and old rats ($P=0.024$). In 1 μ M quinpirole (b), statistical significance was revealed between the young and old-aged rats ($P=0.046$). * $P<0.05$

Another strategy to manipulate the D₂R density in the striatum is gene transfer. This intervention would provide a more specific manipulation of DA function than offered by neural tissue grafting. To this end, we developed methods using adenoviral vectors for intracerebral D₂R gene transfer.

Vector construction

Details of the vector construction are documented elsewhere (Ikari et al. 1995). In brief, the vector was constructed by deletion of the majority of E1 and a portion of E3 region, and insertion of an expression cassette containing the rat D₂R cDNA along with the cytomegalovirus immediate early promoter and enhancer (AdCMV.DopD₂R).

In-vitro expression

By using HeLa cell lines, which normally do not express D₂R, the viability of the viral vector,

AdCMV.DopD₂R was confirmed in vitro. In membrane preparations extracted from HeLa cells infected with AdCMV.DopD₂R, specific binding of [³H] spiperone, a D₂R ligand, was very evident showing the protein expression of D₂R in cellular membrane along with abundant mRNA production.


In-vivo expression and functional assessment

Autoradiographic studies demonstrated that this vector system accomplished similar D₂R overexpression in the brains of Sprague-Dawley and Fischer-344 rats (Fig. 3) (Umegaki et al. 1997; Ingram et al. 1998). However, the overexpression of D₂R was transient. The maximum expression was observed as early as 2 or 3 days after



Fig. 3 Increased expression of D₂R in rat striatum. Representative autoradiographic images of [¹²⁵I]iodosulpride binding in striatal slices are shown for Sprague-Dawley (SD) and Fischer-344 (F344) rats. The striatal slices (10- μ m thickness) were incubated with 0.125 nM [¹²⁵I]iodosulpride for 30 min. Note the greater binding (darker images) near sites of AdCMV.DopD₂R striatal injection (left side for F344 rats; right side for SD rats on this figure) compared with contralateral AdCMV.Null striatal injection

Fig. 4 Time-course of increased D₂R expression. At each time-point, the ratio (AdCMV.DopD₂R-injected striatum/AdCMV.Null-injected striatum) of the mean density (\pm SEM) of grains in the autoradiographic images using [¹²⁵I] iodopsulpride as a ligand is shown. Two representative slices, which exhibited the highest levels of expression, were taken from four rats of each strain for each time-point



vector injection, and expression had declined to almost baseline levels by 3 weeks post-injection (Fig. 4).

To determine if the expressed D₂R by AdCMV.DopD₂R was functional, we selected to use the apomorphine-induced rotational model described earlier (Pycock 1980). The unilateral striatal injection of

the adenoviral vectors would be designed to induce upregulation of D₂R similar to what occurs in the injected side to 6OHDA lesioned rats. We would then expect to observe rotational behavior toward the ipsilateral side of the injection. By using this model, we demonstrated that striatal D₂R induced by the gene transfer with the AdCMV.DopD₂R was functional (Fig. 5) despite the non-selective character of the gene transfer; i.e., many different types of neurons and glia appeared to be expressing D₂R following the vector treatment.




Fig. 5 Apomorphine-induced rotational behavior reflects the functionality of increased D₂R expression. Represented are the group means (\pm SEM) for the net number of rotations (number of turns ipsilateral to the AdCMV.DopD₂R-injected striatum subtracted from the number of turns contralateral to the AdCMV.Dop D₂R-injected striatum) induced by apomorphine (1 mg/ kg). Experimental groups ($n=10$) received unilateral striatal injection of AdCMV.Dop D₂R and AdCMV.Null contralateral striatum. *R: D₂R* refers to AdCMV.Dop D₂R injected into right striatum and AdCMV.Null injected into left striatum, *L: D₂R* refers to AdCMV.Dop D₂R injected into left striatum and AdCMV.Null injected into right striatum, *Control* refers to AdCMV.Null injected bilaterally ($n=11$). * $P<0.05$ from control


Expression in aged rats

By taking advantage of PET technology designed for small animals (Ogawa et al. 2000; Umegaki et al. 2002), we showed that AdCMV.DopD₂R-mediated gene transfer of D₂R was feasible in aged rats (Figs. 6, 7). We also found that the overexpression period of D₂R induced by gene transfer was longer in aged rats than in young rats (Fig. 8) (Umegaki et al. 2003).

Application of gene transfer to age-associated alterations in DA-ACh interactions

To test the hypothesis that D₂R augmentation by adenoviral vector-mediated gene transfer could ameliorate the control of the ACh release by DA, we performed microdialysis studies of vector-injected rats (Umegaki et al. 2006). Quinpirole, a specific D₂R agonist (Sigma, St. Louis, Mo., USA) was infused at

Fig. 6 Brain PET image of the adenoviral vectors-injected rat brain scanned with [^{11}C]raclopride by coronal section at bregma (a–d). The images of a, b and c, d are taken from the same individuals, respectively. Right striatum was injected with AdCMV.DopD₂R. **a** Young rat at day 3 after vector injection. **b** Young rat at day 10 after vector injection. **c** Old rat at day 3 after vector injection. **d** Old rat at day 10 after vector injection. The PET images were acquired for 20 min, starting 20 min after the tracer injection. **e, f** Ex-vivo autoradiography images of the adenoviral vectors-injected rat brain with [^{11}C]raclopride at day 3 after vector injection. The AP coordinate was -0.5 mm from the bregma. **e** Young rat; **f** old rat



a concentration of $0.1 \mu\text{M}$ through the microdialysis probe and ACh levels were then analyzed using a high-performance liquid chromatographic assay. Figure 9 shows the striatal release of ACh when $0.1 \mu\text{M}$ quinpirole was infused in control-vector-injected or AdCMV.DopD₂R-injected old rats. The old rats exhibited significantly less ACh decrease than the young controls ($P=0.014$). The AdCMV.DopD₂R injection significantly restored the release of ACh of old rats ($P=0.006$). We documented a significant difference among the three groups ($P<0.001$) and also showed statistically significant differences between AdCMV.DopD₂R and AdCMV.LacZ-injected old rats

($P=0.006$), and between AdCMV.LacZ-injected young and old rats ($P=0.014$).

The response of cholinergic neurons in aged striatum was compatible with the results of our previous study when $0.1 \mu\text{M}$ of quinpirole was infused (Kurotani et al. 2003). The D₂R gene-transferred rats showed significantly stronger responses of striatal cholinergic neurons to the D₂R agonist infusion compared with control-vector-treated rats.

The successful restoration of age-associated functional decline of DA-ACh interactions in the striatum stimulated several suggestions. First, the age-associated decrease of D₂R appears at least partly involved




Fig. 7 Binding potential for [¹¹C]raclopride in both Ad.CMV.DopD₂R- and Ad.CMV.LacZ-injected striata of the three age groups (5, 13, 24 months) of rats 2 or 3 days after the vector injection (5C, 13C, and 24C stand for the Ad.CMV.LacZ-injected striata in 5-, 13-, and 24-month-old rats, respectively, and 5D, 13D, and 24D stand for the Ad.CMV.DopD₂R-injected striata in 5-, 13-,

and 24-month-old rats, respectively). All data were expressed mean \pm SD ($n=12-25$). The paired *t*-test between Ad.CMV.DopD₂R-injected side and Ad.CMV.LacZ-injected side in each age group showed significant increase of binding potential in Ad.CMV.DopD₂R-injected side ($P<0.01$ in each age group). ** $P<0.01$




Fig. 8 Time-course of binding potential from day 2 or 3 to day 10 after vector injection in three age groups. Each rat of the three groups underwent three PET scans: $n=8$ for 5-months old, $n=5$ for 13-months old, and $n=9$ for 24-months old. Data at day 7 and day 10 were expressed as percentages of the Ad.CMV.DopD₂R-injected side to Ad.CMV.LacZ-injected side ratio of binding potential at day 2 or day 3; i.e., the largest Ad.CMV.DopD₂R-injected side to Ad.CMV.LacZ-injected side ratio observed at day 2 or day 3 in each group was normalized as 100. Data are expressed as mean \pm SD. Repeated ANOVA showed significant difference among three groups ($P=0.0112$), and Scheffé's post-hoc analysis showed the significant difference between the 5- and 24-month-old groups at days 7 and day 10 ($P=0.0007$, and <0.0001 , respectively)




Fig. 9 Time-courses of ACh release in AdCMV.DopD₂R old (●) and AdCMV.LacZ injected old (○) and young (▼) rats are shown. The results are expressed as a percentage of the basal levels (calculated as the mean of the three samples before drug perfusion). Each point represents the mean \pm SD. Quinpirole at the concentration of 0.1 μ M was perfused through the microdialysis probe from 60 to 240 min after the experiment was begun. Repeated-measures ANOVA revealed a significant difference among three groups ($P<0.001$), and Scheffé's post-hoc analysis showed a statistically significant difference between AdCMV.DopD₂R and AdCMV.LacZ-injected old rats ($P=0.006$), and between AdCMV.LacZ-injected young and old rats ($P=0.014$)

in the mechanism affected by the age-associated deterioration of ACh control of dopaminergic input. Second, age-associated functional decline in the brain could be improved by several modalities including gene transfer. Third, the prevention of age-associated functional decline would be the best strategy; however, it also appeared that interventions were possible after age-associated functional decline manifested. The challenge now is find interventions that can act in a long-term and safe fashion to maintain striatal function.

Summary

With age both functional and anatomical alterations occur in the nigrostriatum system. Of these alterations, decline of D₂R numbers in the striatum is one of the most established features of mammalian brain aging. Functional interactions of DA and ACh in the striatum are also changed; specifically, inhibition of ACh release by D₂R stimulation is reduced in aged striatum, possibly due to age-associated decrease of D₂R in the cholinergic interneurons. By taking advantage of gene transfer technology, we demonstrated that D₂R augmentation ameliorated the control of the ACh release by DA. Our studies suggested that age-associated decrease of D₂R contributes to functional alteration of the interaction of DA and ACh in the striatum and these age-associated changes indeed are modifiable. Future studies are warranted to see if the functional restoration of the nigrostriatum DA system could lead to motor functional improvement in aged animals and by extension in aged humans.

References

- Berg MJ, Ebert B, Willis DK, Host T, Fincham RW, Schottelius DD (1987) Parkinsonism-drug treatment. Part I. Drug Intell Clin Pharm 21:10–21
- Bolam JP, Bennett BD (1995) Microcircuitry of the neostriatum. In: Ariano MA, Surmeier DJ (eds) Molecular and cellular mechanisms of neostriatal function. Landes, Austin
- Calabresi P, Centonze D, Gubellini P, Pisani A, Bernardi G (2000) Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23:120–126
- Carlsson A, Winblad B (1976) Influence of age and time interval between death and autopsy on dopamine and 3-methoxytyramine levels in human basal ganglia. J Neural Transm 38:271–276
- Carp JS, Anderson RJ (1979) Sensorimotor deficits produced by phenytoin and chlorpromazine in unanesthetized cats. Pharmacol Biochem Behav 10:513–520
- Chang HT (1988) Dopamine-acetylcholine interaction in the rat striatum: a dual-labeling immunocytochemical study. Brain Res Bull 21:295–230
- Contant C, Umbriaco D, Garcia S, Watkins KC, Descarries L (1996) Ultrastructural characterization of the acetylcholine innervation in adult rat neostriatum. Neuroscience 71:937–944
- Das A, Dikshit M, Nath C (2001) Profile of acetylcholinesterase in brain areas of male and female rats of adult and old age. Life Sci 68:1545–1555
- DeBoer P, Heeringa MJ, Abercrombie ED (1996) Spontaneous release of acetylcholine in striatum is preferentially regulated by inhibitory dopamine D₂ receptors. Eur J Pharmacol 317:257–262
- Delbono O (2003) Neural control of aging skeletal muscle. Aging Cell 2:21–29
- Della Vedova F, Fumagalli F, Sacchetti G, Racagni G, Brunello N (1992) Age-related variations in relative abundance of alternative spliced D₂ receptor mRNAs in brain areas of two rat strains. Brain Res Mol Brain Res 12:357–359
- Di Chiara G, Morelli M, Consolo S (1994) Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends Neurosci 17:228–233
- Dimova R, Vuillet J, Nieoullon A, Kerkerian-Le Goff L (1993) Ultrastructural features of the choline acetyltransferase-containing neurons and relationships with nigral dopaminergic and cortical afferent pathways in the rat striatum. Neuroscience 53:1059–1071
- Dorfman LJ, Bosley TM (1979) Age-related changes in peripheral and central nerve conduction in man. Neurology 29:38–44
- Dutta C, Hadley EC, Lexell J (1997) Sarcopenia and physical performance in old age: overview. Muscle Nerve 5:S5–S9
- Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 991:1–14
- Gage NH, Dunnett SB, Stenevi U, Bjorklund A (1983) Aged rats: recovery of motor impairments by intrastriatal nigral grafts. Science 221:966–969
- Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 13:244–254
- Han Z, Kuyatt BL, Kochman KA, DeSouza EB, Roth GS (1989) Effect of aging on concentrations of D₂-receptor-containing neurons in the rat striatum. Brain Res 498:299–307
- Henry JM, Roth GS (1984) Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade. Life Sci 35:899–904
- Henry JM, Joseph JA, Kochman K, Roth GS (1987) Effect of aging on striatal dopamine receptor subtype recovery following N-ethoxycarbonyl -2-ethoxy-1,2-dihydroquinoline blockade and relation to motor function in Wistar rats. Brain Res 418:334–342
- Herman JP, Lupp A, Abrous N, Le Moal M, Hertting G, Jackisch R (1988) Intrastriatal dopaminergic grafts restore inhibitory control over striatal cholinergic neurons. Exp Brain Res 73:236–248

- Ikari H, Zhang L, Chernak JM, Mastrangeli A, Kato S, Kuo H, Crystal RG, Ingram DK, Roth GS (1995) Adenovirus-mediated gene transfer of dopamine D₂ receptor cDNA into rat striatum. *Brain Res Mol Brain Res* 34:315–320
- Ingram DK, Ikari H, Umegaki H, Chernak JM, Roth GS (1998) Application of gene therapy to treat age-related loss of dopamine D₂ receptor. *Exp Gerontol* 33:793–804
- Jackisch R, Duschek M, Neufang B, Rensing H, Hertting G, Herman JP (1991) Long-term survival of intrastriatal dopaminergic grafts: modulation of acetylcholine release by graft-derived dopamine. *J Neurochem* 57:267–276
- Joseph JA, Roth GS (1988a) Upregulation of striatal dopamine receptors and improvement of motor performance in senescence. *Ann N Y Acad Sci* 515:355–356
- Joseph JA, Roth GS (1988b) Altered striatal dopaminergic and cholinergic reciprocal inhibitory control and motor behavioral decrements in senescence. *Ann N Y Acad Sci* 521:110–122
- Joseph JA, Roth GS, Strong R (1990) The striatum, a microcosm for the examination of age-related alterations in the CNS. Review of biological research in aging. Liss, New York
- Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, Pastan I, Nakanishi S (2000) Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. *Science* 289:633–637
- Kolb B, Forgie M, Gibb R, Gorny G, Rowntree S (1998) Age, experience and the changing brain. *Neurosci Biobehav Rev* 22:143–159
- Kozlowski MR, Marshall JF (1981) Plasticity of neostriatal metabolic activity and behavioral recovery from nigrostriatal injury. *Exp Neurol* 74:318–323
- Kubota Y, Inagaki S, Shimada S, Kito S, Eckenstein F, Tohyama M (1987) Neostriatal cholinergic neurons receive direct synaptic inputs from dopaminergic axons. *Brain Res* 413:179–184
- Kurotani S, Umegaki H, Ishiwata K, Suzuki Y, Iguchi A (2003) The age-associated changes of dopamine-acetylcholine interaction in the striatum. *Exp Gerontol* 38:1009–1013
- Lapper SR, Bolam JP (1992) Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. *Neuroscience* 51:533–545
- Lexell J (1997) Evidence for nervous system degeneration with advancing age. *J Nutr* 127:1011S–1013S
- Marshall JF, Berrios N (1979) Movement disorders of aged rats: reversal by dopamine receptor stimulation. *Science* 206:477–479
- Maurice N, Mercer J, Chan CS, Hernandez-Lopez S, Held J, Tkatch T, Surmeier DJ (2004) D₂ dopamine receptor-mediated modulation of voltage-dependent Na⁺ channels reduces autonomous activity in striatal cholinergic interneurons. *J Neurosci* 24:10289–10301
- Mensah PL (1980) Distribution of the largest neuron in mouse caudate-putamen nucleus: its position in large-cell-medium-cell clusters. *Exp Brain Res* 38:267–271
- Morgan DG, Finch CE (1988) Dopaminergic changes in the basal ganglia. A generalized phenomenon of aging in mammals. *Ann N Y Acad Sci* 515:145–160
- Norman AB, Battaglia G, Creese I (1987) Differential recovery rates of rat D₂ dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. *J Neurosci* 7:1484–1491
- Ogawa N, Asanuma M, Kondo Y, Nishibayashi S, Mori A (1994) Reduced choline acetyltransferase activity and muscarinic M1 receptor levels in aged Fisher 344 rat brains did not parallel their respective mRNA levels. *Brain Res* 658:87–92
- Ogawa O, Umegaki H, Ishiwata K, Asai Y, Ikari H, Oda K, Toyama H, Ingram DK, Roth GS, Iguchi A, Senda M (2000) In vivo imaging of adenovirus-mediated overexpression of dopamine D₂ receptors in rat striatum by positron emission tomography. *Neuroreport* 11:743–748
- Pickel VM, Chan J (1990) Spiny neurons lacking choline acetyltransferase immunoreactivity are major targets of cholinergic and catecholaminergic terminals in rat striatum. *J Neurosci Res* 25:263–280
- Pickel VM, Chan J (1991) Plasmalemmal appositions between cholinergic and non-cholinergic neurons in rat caudate-putamen nuclei. *Neuroscience* 41:459–472
- Pisani A, Bonsi P, Centonze D, Calabresi P, Bernardi G (2000) Activation of D₂-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. *J Neurosci* 20:RC69
- Pisani A, Bonsi P, Picconi B, Tolu M, Giacomini P, Scarnati E (2001) Role of tonically-active neurons in the control of striatal function: cellular mechanisms and behavioral correlates. *Prog Neuropsychopharmacol Biol Psychiatry* 25:211–213
- Potvin AR, Syndulko K, Tourtellotte WW, Lemmon JA, Potvin JH (1980) Human neurologic function and the aging process. *J Am Geriatr Soc* 28:1–9
- Puschban Z, Scherfler C, Granata R, Laboyrie P, Quinn NP, Jenner P, Poewe W, Wenning GK (2000) Autoradiographic study of striatal dopamine re-uptake sites and dopamine D₁ and D₂ receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. *Neuroscience* 95:377–388
- Pycock CJ (1980) Turning behaviour in animals. *Neuroscience* 5:461–514
- Rech RH, Borys HK, Moore KE (1966) Alterations in behavior and brain catecholamine levels in rats treated with alpha-methyltyrosine. *J Pharmacol Exp Ther* 153:412–499
- Roth GS, Joseph JA (1994) Cellular and molecular mechanisms of impaired dopaminergic function during aging. *Ann N Y Acad Sci* 719:129–135
- Sherman KA, Friedman E (1990) Pre- and post-synaptic cholinergic dysfunction in aged rodent brain regions: new findings and an interpretative review. *Int J Dev Neurosci* 8:689–708
- Stoof JC, Drukarch B, de Boer P, Westerink BH, Groenewegen HJ (1992) Regulation of the activity of striatal cholinergic neurons by dopamine. *Neuroscience* 47:755–770
- Stark AK, Pakkenberg B (2004) Histological changes of the dopaminergic nigrostriatal system in aging. *Cell Tissue Res* 318:81–92
- Tepper JM, Bolam JP (2004) Functional diversity and specificity of neostriatal interneurons. *Curr Opin Neurobiol* 14:685–689
- Umegaki H, Chernak JM, Ikari H, Roth GS, Ingram DK (1997) Rotational behavior produced by adenovirus-mediated

- gene transfer of dopamine D₂ receptor into rat striatum. *Neuroreport* 8:3553–3558
- Umegaki H, Ishiwata K, Ogawa O, Ingram DK, Roth GS, Yoshimura J, Oda K, Matsui-Hirai H, Ikari H, Iguchi A, Senda M (2002) In vivo assessment of adenoviral vector-mediated gene expression of dopamine D(2) receptors in the rat striatum by positron emission tomography. *Synapse* 43:195–200
- Umegaki H, Ishiwata K, Ogawa O, Ingram DK, Roth GS, Oda K, Kurotani S, Kawamura K, Wang WF, Ikari H, Senda M, Iguchi A (2003) Longitudinal follow-up study of adenoviral vector-mediated gene transfer of dopamine D₂ receptors in the striatum in young, middle-aged, and aged rats: a positron emission tomography study. *Neuroscience* 121:479–486
- Umegaki H, Yamaguchi Y, Ishiwata K, Ingram DK, Roth GS, Iguchi A (2006) Functional recovery of the striatal cholinergic system in aged rats by adenoviral vector-mediated gene transfer of dopamine D₂ receptor. *Mech Ageing Dev* 127:813–815
- Wang L, Albrecht MA, Wurtman RJ (2007) Dietary supplementation with uridine-5'-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat. *Brain Res* 1133:42–48
- Weiss B, Chen JF, Zhang S, Zhou LW (1992) Developmental and age-related changes in the D₂ dopamine receptor mRNA subtypes in rat brain. *Neurochem Int* 20:49S–58S
- Wu CF, Bertorelli R, Sacconi M, Pepeu G, Consolo S (1988) Decrease of brain acetylcholine release in aging freely-moving rats detected by microdialysis. *Neurobiol Aging* 9:357–361
- Yan Z, Song WJ, Surmeier J (1997) D₂ dopamine receptors reduce N-type Ca²⁺ currents in rat neostriatal cholinergic interneurons through a membrane-delimited, protein-kinase-C-insensitive pathway. *J Neurophysiol* 77:1003–1015
- Zambrzycka A, Alberghina M, Strosznajder JB (2002) Effects of aging and amyloid-beta peptides on choline acetyltransferase activity in rat brain. *Neurochem Res* 27:277–281
- Zhang L, Ravipati A, Joseph J, Roth GS (1995) Aging-related changes in rat striatal D₂ receptor mRNA-containing neurons: a quantitative nonradioactive in situ hybridization study. *J Neurosci* 15:1735–1740